Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Looking in the Mirror: The Moth Podcast 18 min · 25 Sep 2026 · The Moth

Trump hosts President Xi at state banquet 31 min · 25 Sep 2026 · Global News Podcast

TNA Reaction: Sawyer & Shaw Arrive 18 min · 25 Sep 2026 · Busted Open

NPR News: 09-25-2026 12AM EDT 5 min · 25 Sep 2026 · NPR News Now

12AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Lair of the White Worm 1h 0m · 25 Sep 2026 · How Did This Get Made?

Report any issue

Source

Recorded01 Nov 2021

Publisherneurology.libsyn.com ↗

Handlerec:5447751

Show notes

In the first part of the podcast, Dr. Gregg Day discusses the importance of patient participation in the decision-making process when considering the use of aducanumab for the treatment of Alzheimer disease with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer's Disease Center. In the second segment, Dr. Andy Southerland talks with Dr. Jyri Virta about the risk of aneurysm rupture after thrombolysis in patients with acute ischemic stroke and unruptured intracranial aneurysms.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in